ReviewBrain Trauma

Exploring New Routes for Neuroprotective Drug Development in Traumatic Brain Injury

See allHide authors and affiliations

Science Translational Medicine  14 Apr 2010:
Vol. 2, Issue 27, pp. 27rv1
DOI: 10.1126/scitranslmed.3000330

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Worldwide, traumatic brain injury (TBI) is a major cause of mortality and morbidity with a substantial predicted increase in incidence. Despite an obvious need, there are no pharmacological treatment options for TBI because translation of neuroprotection from preclinical studies to clinical practice has so far failed. Here, we identify potential causes for this failure. We suggest that the monitoring and investigation tools that are commonly used in patients with TBI may provide an experimental medicine route to facilitate a more rational approach to translational research. This suggestion is underpinned by existing research data on disease biology, drug delivery, and treatment response obtained with these methods.


    View Full Text

    Stay Connected to Science Translational Medicine